**Supplementary Materials and Methods**

**Double-label IHC and Neutralization : Detailed Information on the antibodies used in this study**

These studies used cell-specific antibodies against surfactant apoprotein C (SP-C, for alveolar type 2 cells) (Millipore, Billerica, MA), Clara Cell 10 kDa Surfactant Protein (CCSP, for airway epithelial cells) (Santa Cruz Biotechnology, Inc, Santa Cruz, CA), and F4/80 (for macrophages) (eBioscience, San Diego, CA), and antibodies against Chi3l1/BRP-39 (Medimmune, Gaithersburg, MD) and Sema7a (Abcam, Inc, Cambridge, MA). The neutralizing antibodies used in these studies were purchased from Invitrogen Life Tech, Cartsbad, CA (Chi3l1/BRP-39), Biolegend San Diego, CA (β1-integrin; 3 integrin), Abcam, Inc, Cambridge, MA (αv-integrin), Santa Cruz Bio, Santa Cruz, CA (α1-integrin) and R&D Systems, Minneapolis, MN (Sema7a-Fc, Plexin C1). Rabbit polyclonal antibodies against LIMK2 and phosphorylated Cofilin were from Santa Cruz Biotechnology and Cell signaling Technology (Danvers, MA), respectively.